Subject(s)
COVID-19 , Extracorporeal Membrane Oxygenation , Heart Diseases , Myocarditis , Thrombosis , COVID-19/complications , Heart Diseases/complications , Heart Diseases/therapy , Humans , Myocarditis/complications , Myocarditis/diagnosis , Myocarditis/therapy , Thrombosis/complications , Thrombosis/therapyABSTRACT
As the number of Advanced Practice Providers (APPs) has increased across health care settings, institutions have identified the need to provide opportunities for the advancement, growth, and development of APPs. An APP Professional Advancement Program was developed and implemented at our freestanding, pediatric academic medical center that employs over 700 APPs. This program was designed to support all APPs regardless of their role and practice setting by recognizing their accomplishments and providing the tools and resources needed to pursue opportunities to further their professional development and leadership. This article describes the development, implementation, and sustainment of an APP Professional Advancement Program.
Subject(s)
Academic Medical Centers , Leadership , Career Mobility , Child , HumansABSTRACT
OBJECTIVE: Objectives To describe the results of a clinical practice pathway (CPP) for the management of postcatheterization pulse loss in a children's hospital. BACKGROUND: Standardized approaches to the diagnosis and management of postcatheterization arterial thrombus are lacking. As a result, substantial practice variation exists. METHODS: Data collected prospectively for quality improvement purposes were retrospectively reviewed. RESULTS: Since initiation of the CPP, 93/1,672 (5.4%) catheterizations resulted in pulse loss at a median patient age and weight of 73 days (1 day-5.8 years) and 4.8 kg (2-14.1 kg). Arterial thrombus was documented by ultrasound (US) in 85. Of these, 66 resolved by 12 weeks of therapy, seven patients died, and four were lost to follow-up before completing treatment. Eight patients had persistent thrombus despite a full treatment course (89% success rate in those able to complete treatment). Of patients treated with unfractionated heparin as initial therapy, 46% (17/37) achieved a therapeutic partial thromboplastin time within 12 hr with 19% (67/343) of all levels therapeutic. As a result, the CPP was modified to use enoxaparin as first line agent, of which 57% (41/72) had a therapeutic anti-Xa level after the 2nd dose and 88% by the 4th dose. No bleeding complications were observed. A priori established process metrics were achieved. CONCLUSIONS: A CPP utilizing early initiation of anticoagulation and US to aid diagnosis of postcatheterization arterial thrombus and response to therapy is feasible and effective. In those able to complete up to 12 weeks of treatment, resolution occurs in nearly 90%. © 2014 Wiley Periodicals, Inc.
Subject(s)
Anticoagulants/administration & dosage , Arterial Occlusive Diseases/drug therapy , Cardiac Catheterization/adverse effects , Critical Pathways , Fibrinolytic Agents/administration & dosage , Outcome Assessment, Health Care , Pulse , Thrombosis/drug therapy , Age Factors , Anticoagulants/adverse effects , Arterial Occlusive Diseases/diagnostic imaging , Arterial Occlusive Diseases/etiology , Arterial Occlusive Diseases/mortality , Arterial Occlusive Diseases/physiopathology , Cardiac Catheterization/mortality , Child , Child, Preschool , Drug Administration Schedule , Fibrinolytic Agents/adverse effects , Hemorrhage/chemically induced , Hospitals, Pediatric , Humans , Infant , Infant, Newborn , Philadelphia , Predictive Value of Tests , Retrospective Studies , Risk Factors , Thrombosis/diagnostic imaging , Thrombosis/etiology , Thrombosis/mortality , Thrombosis/physiopathology , Time Factors , Treatment Outcome , UltrasonographyABSTRACT
BACKGROUND: This is the first study to systematically manipulate duration of voucher-based reinforcement therapy (VBRT) to see if extending the duration increases abstinence during and following VBRT. METHODS: We randomized cocaine-dependent methadone-maintained adults to Standard (12 weeks; n=62) or Extended (36 weeks; n=68) VBRT and provided escalating voucher amounts contingent upon urinalysis verification of cocaine abstinence. Urinalysis was scheduled at least every 2 weeks during the 48-week study and more frequently during VBRT (3/week) and 12 weeks of Aftercare (2/week). RESULTS: Extended VBRT produced longer durations of continuous cocaine abstinence during weeks 1-24 (5.7 vs 2.7 weeks; p=0.003) and proportionally more abstinence during weeks 24-36 (X(2)=4.57, p=.03, OR=2.18) compared to Standard VBRT. Duration of VBRT did not directly predict after-VBRT abstinence; but longer continuous abstinence during VBRT predicted abstinence during Aftercare (p=0.001) and during the last 12 weeks of the study (p<0.001). Extended VBRT averaged higher monthly voucher costs compared to Standard VBRT ($96 vs $43, p<.001); however, the average cost per week of abstinence attained was higher in the Standard group ($8.06 vs $5.88, p<.001). Participants in the Extended group with voucher costs exceeding $25 monthly averaged 20 weeks of continuous abstinence. CONCLUSIONS: Greater abstinence occurred during Extended VBRT, but providing a longer duration was not by itself sufficient to maintain abstinence after VBRT. However, if abstinence can be captured and sustained during VBRT, then providing longer durations may help increase the continuous abstinence that predicts better long-term outcomes.
